BioVersys AG | Finanzwire

BRIEF

published on 03/19/2025 at 07:05, 10 months 11 days ago

First Patient Dosed in Alpibectir-Ethionamide TB Trial

Phase 2 Trial GSK Collaboration BioVersys Alpibectir-Ethionamide Tuberculosis
PRESS RELEASE

published on 03/19/2025 at 07:00, 10 months 11 days ago

FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
First patient dosed in 14-day Phase 2 clinical trial evaluating Alpibectir-Ethionamide with first-line TB drugs under BioVersys and GSK collaboration for pulmonary TB patients

GSK Phase 2 BioVersys Alpibectir-Ethionamide TB
BRIEF

published on 03/14/2025 at 07:05, 10 months 16 days ago

BioVersys Sets March 26 for Full-Year 2024 Financial Results Release

Financial Results Conference Call Biopharmaceutical Antibacterial Products BioVersys
PRESS RELEASE

published on 03/14/2025 at 07:00, 10 months 16 days ago

BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG announces reporting date for full-year 2024 financial results and event details, including a conference call and webcast on March 26, 2025. The company focuses on developing novel antibacterial products for MDR bacteria

Financial Results Conference Call BioVersys AG Antibacterial Products MDR Bacteria
BRIEF

published on 03/10/2025 at 07:05, 10 months 20 days ago

BioVersys AG Announces Partial Exercise of Over-Allotment Option

Biopharmaceutical Company SIX Swiss Exchange Over-allotment Option BioVersys IPO Antibacterial Products
PRESS RELEASE

published on 03/10/2025 at 07:00, 10 months 20 days ago

Bioversys announces partial exercise of over-allotment option
BioVersys announces partial exercise of over-allotment option following successful IPO on the SIX Swiss Exchange, raising total gross proceeds of CHF76.7 million

Biopharmaceutical Company IPO Over-allotment Option BioVersys Multidrug-resistant Bacteria
BRIEF

published on 02/11/2025 at 07:05, 11 months 19 days ago

BioVersys Advances BV500 NTM Program with CF AMR Syndicate Support

Cystic Fibrosis BioVersys AG NTM Program LifeArc Support Ansamycin Chemistry
PRESS RELEASE

published on 02/11/2025 at 07:00, 11 months 19 days ago

BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria

BioVersys BV500 NTM Program CF AMR Syndicate NTM Lung Disease MDR Bacteria
BRIEF

published on 02/06/2025 at 07:05, 11 months 24 days ago

BioVersys Successfully Completes IPO at CHF 36 per Share

IPO Market Capitalization SIX Swiss Exchange BioVersys AG Antibacterial Drugs
PRESS RELEASE

published on 02/06/2025 at 07:00, 11 months 24 days ago

BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria

IPO SIX Swiss Exchange Antibacterial Products BioVersys CHF 36

Published on 01/31/2026 at 03:15, 3 hours 12 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 4 hours 7 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 4 hours 47 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 6 hours 27 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 7 hours 27 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 3 hours 41 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 8 hours 27 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 10 hours 16 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 10 hours 17 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 10 hours 19 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 12 hours 42 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 22 hours 27 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 12 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 12 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 12 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News